Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
 
Feedback
Home
c19early.org COVID-19 treatment researchSelect treatment..Select..
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

LL-37 for COVID-19

LL-37 has been reported as potentially beneficial for treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Zhao et al., Efficacy and safety of Oral LL‐37 against the Omicron BA.5.1.3 variant of SARS‐COV‐2: A randomized trial, Journal of Medical Virology, doi:10.1002/jmv.29035
AbstractRecombinant LL‐37 Lactococcus lactis (Oral LL‐37) was designed to prevent progression of COVID‐19 by targeting virus envelope, however, effectiveness and safety of Oral LL‐37 in clinical application was unclear. A total of 238 adult inpatients, open‐labelled, randomized, placebo‐controlled, single‐center study was conducted to investigate the primary end points, including negative conversion time (NCT) of SARS‐CoV‐2 RNA and adverse events (AEs). As early as intervened on 6th day of case confirmed, Oral LL‐37 could significantly shorten NCT (LL‐37 9.80 ± 2.67 vs. placebo 14.04 ± 5.89, p < 0.01). For Oral LL‐37, as early as treated in 6 days, the adjusted hazard ratio (HR) for a primary event of nucleic acid negative outcome was 6.27‐fold higher than 7‐day‐later (HR: 6.276, 95% confidence interval [CI]: 3.631–10.848, p < 0.0001), and the adjusted HR of Oral LL‐37 within 6 days is higher than placebo (HR: 2.427 95% CI: 1.239–4.751, p = 0.0097). No severe AEs were observed during hospitalization and follow‐up investigation. This study shows that early intervention of Oral LL‐37 incredibly reduces NCT implying a potential for clearance of Omicron BA.5.1.3 without evident safety concerns.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit